Is Veozah effective in treating hot flashes

Veozah is effective in treating hot flashes. By blocking the patient's NK3 receptor, it significantly reduces the severity and frequency of hot flashes. Fezonatant (Veozah) works by binding to and blocking the activity of NK3 receptors, which play a role in the brain's regulation of body temperature. (Veozah) is the first oral non-hormonal NK3 receptor antagonist approved by the US FDA for the treatment of hot flashes, which will bring good news to tens of thousands of menopausal women.

Trial effects of Veozah

In a preliminary analysis of the Phase 2b VESTA study, oral fezonatan (Veozah) reduced the frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis assessed the impact of fezonatant (Veozah) on response rates and patient reports (PROs).

Test method

In this 12-week, double-blind study, postmenopausal women with moderate/severe VMS were randomized to receive 15, 30, 60, or 90 mg of Veozah BID or 30, 60, or 120 mg QD, or placebo. The proportion of responders is based on daily diary recordings of VMS reductions. Logistic regression was used to calculate P values ​​for comparisons between active treatment and placebo. Changes from baseline in PROs (Menopause-Specific Quality of Life Questionnaire, Heat Flash-Related Daily Interference Scale, Green Menopause Scale) were measured using mixed models for repeated measures, and post hoc differences were compared with published minimally important differences (MIDs).

Test results

Of 356 randomized women, 352 received treatment and were analyzed. A greater proportion of women receiving Veozah met efficacy definitions at Week 12 compared with placebo. For all, at week 4 (placebo: -1.8; Veozah: range, -1.9 to -3.6) and week 12 (placebo: -2.3; Veozah: range: -2.9 to -2.9 -4.4), the mean change from baseline in the Menopause-Specific Quality of Life Questionnaire VMS score exceeded MID (1.2) (placebo: -2.9; fezolinant: range, -3.3 to -4.3) exceeded MID (1.76).

Greene Climatic Scale VMS domain scores improved for most Veozah doses compared with placebo (Week 4, placebo: -1.7; Veozah: range, -2.1 to -3.3; Week 12, placebo; -2.1; Veozah, range, -2.7 to -3.6).

Test conclusion

Compared with placebo, oral fezonatan (Veozah) was more effective and resulted in greater improvements in quality of life and other PRO measures, including reducing the interference of VMS on daily life.

Where to purchase Veozah

Veozah (Veozah) is not currently on the market in mainland China. There are currently two main channels for purchasing the drug. One is to purchase it in areas where it has been launched, but the journey is long and the requirements will increase; the other is to obtain it through the help of domestic professional overseas medical service organizations (such as Medical Companion Travel). The drug can be mailed to your home, signed a contract, guaranteed to be authentic, and more cost-effective. However, the price of the drug is restricted by many factors and is not fixed. It is recommended to consult customer service personnel for specific costs and acquisition procedures.

Recommended related articles:

References

Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 Dec;27(12):1350-1356. doi: 10.1097/GME.0000000000001621. PMID: 32769757; PMCID: PMC7709922.